重庆华森制药股份有限公司关于公司收到药品再注册批准通知书的公告

Core Points - Chongqing Huasen Pharmaceutical Co., Ltd. has received approval from the Chongqing Municipal Drug Administration for the re-registration of two drugs: Pediatric Throat Granules and Diammonium Glycyrrhizinate for Injection [1][2][6] Group 1: Drug Registration Information - Pediatric Throat Granules are indicated for clearing heat and relieving throat pain, used for children with symptoms such as sore throat, cough with phlegm, and acute pharyngitis [2][4] - Diammonium Glycyrrhizinate for Injection is used for acute and chronic viral hepatitis with elevated alanine aminotransferase (ALT) levels, exhibiting anti-inflammatory and hepatoprotective effects [3][5] Group 2: Market Context - The pediatric traditional Chinese medicine market has reached a record high of 18.3 billion yuan in 2024, with pediatric cold medications accounting for 37.23% and cough medications for 34.40% of the market share [4] Group 3: Company Impact - The approval of the re-registration will ensure the normal production and sales of the drugs, allowing the company to maintain high product quality [6]